This past week, we reached a milestone that is nothing short of extraordinary. Our very first patients received the Ocumetics Accommodating Intraocular Lens. Just one week later, they are recovering well—and importantly, no complications have been observed.

I cannot overstate how meaningful this moment is. For years, we have poured our hearts, energy, and belief into making the Ocumetics Lens a reality. To now see it safely implanted and beginning to change lives is remarkable. These are the moments we dreamed of.

The early signs are encouraging and give us confidence as we move forward with the next surgical day and complete the first group of patients. The real test lies ahead, as healing continues and vision outcomes begin to emerge.

This achievement is proof that bold ideas, relentless effort, and true teamwork can change the world. And make no mistake—we are changing the world.

Thank you for believing. Thank you for persevering. And thank you for standing shoulder to shoulder with us on this journey. Together, we are making history.

With pride and gratitude,

Dean Burns
President, CEO and Director
Ocumetics Technology

  • Ocumetics Announces Initiation of Patient Recruitment for Upcoming Group Two Human Clinical Surgeries

    Key Highlights Group Two clinical study underway – Patient recruitment has begun in Mexico City, with surgeries targeted for Fall 2026. Moving beyond safety – The Group Two study will evaluate the Ocumetics Lens for safety plus near-and distance-vision performance. Next-generation technology – Patients will receive the latest-generation Ocumetics Lens implanted with an enhanced delivery system. 12-month data milestone approaching – Group One patients are

  • Ocumetics Announces Completion of Third and Final Tranche of Unit Private Placement

    Calgary, Alberta – TheNewswire – August 24, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the third and final tranche of the private placement previously announced by the Corporation on July 7, July 29, July 30, 2026 and July 31, 2026 (the “Offering”).   The Corporation

  • Ocumetics Accelerates Toward Group Two First-In-Human Study with Manufacturing Launch of Optimized Accommodating Lens

    Key Highlights Precision molds received for manufacturing of new optimized accommodating intraocular lenses Production and testing of next-generation lenses now underway New lens design incorporates insights from Group One First-in-Human study Group Two preclinical surgeries targeted for early Q3 2026 FDA Investigational Device Exemption (IDE) preparation advancing Calgary, Canada – TheNewswire – May 12, 2026

  • Ocumetics Announces Offering of Units

    Calgary, Alberta – TheNewswire – April 29, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to